Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2013

View Archived Issues

Results show excellent reproducibility of in vivo [11C]-PBR-28 binding in MS

Recombinant BCG vaccine found safe and immunogenic in phase I study

Ferumoxytol-enhanced MRI shows potential for neuroimaging of patients with HAND

Identification of a novel DYRK1A inhibitor with the potential to prevent memory impairment in vivo

In vivo results suggest HIS-601 is a promising candidate for metabolic disorders

Merrimack Pharmaceuticals reports phase II MM-121 study results

Aragon Pharmaceuticals doses first patient in phase I study of ARN-810

X-Body Biosciences forms therapeutic antibody alliance

Gene silencing construct Tribetarna increases survival in lung cancer model

Promising interim results seen in phase III Lymphoseek trial in head and neck cancer

Astellas to collaborate with Ambrx on antibody-drug conjugates for cancer

Arena Pharmaceuticals begins phase I trial of APD-334

New antimalarial agents prepared at CSIR

Covis Pharma to acquire U.S. rights to several sanofi-aventis drugs

Otsuka Pharmaceutical patents novel prodrugs of brexpiprazole

Vertex and Bristol-Myers Squibb to conduct phase II studies of VX-135 and daclatasvir

Vital Therapies enrolls first patient in phase III trial of the ELAD system

A*STAR and Singapore Health Services synthesize new agents for bacterial infections

Clinical data on OTX-008 presented at AACR meeting

Blanchette Rockefeller Neurosciences Institute and Neurotrope BioScience form collaboration

VaxInnate receives NIH grant to develop recombinant tetravalent dengue vaccine

Novel itraconazole analogues designed by Johns Hopkins University

Roche presents new compounds for atherosclerosis and other disorders

Shire commences two phase II studies of product designed to facilitate hemodialysis

EMA extends review of Scenesse MAA for erythropoietic protoporphyria

FDA grants priority review for Bayer's riociguat NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...